Multiple Sclerosis Trial, Recruiting (NCT06161376)

Multiple Sclerosis Trial, Recruiting NCT06161376 Sponsor: University Hospital, Toulouse Condition: Multiple Sclerosis

Printed from Voxsanity (voxsanity.com.au) — NCT06161376 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Multiple Sclerosis

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who live in France and are enrolled in the French social security system
People who have been diagnosed with multiple sclerosis (based on a standard set of medical guidelines called the McDonald 2017 criteria), whether or not they are currently on treatment for it
People who are already scheduled to have a bladder function test (called a urodynamic assessment) as part of their usual care

Who may not be able to join:

People who are pregnant or breastfeeding
People who are under legal guardianship
People who have a urinary tract infection that has not yet been treated at the time of joining the trial
People who have a known blockage in the urinary tract below the bladder, a known pelvic floor disorder, a type of bladder or urinary tract cancer called urothelial carcinoma, a chronic bladder condition called interstitial cystitis, or who have had a surgical procedure to enlarge the bladder (called augmentation cystoplasty)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 14 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Xavier Game, MD, University Hospital, Toulouse

Phone: 05 61 32 33 01

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06161376

Sponsor: University Hospital, Toulouse

Phase: Not Applicable

Status: Recruiting

Condition: Multiple Sclerosis

Trial contact: 05 61 32 33 01

More information: https://clinicaltrials.gov/study/NCT06161376

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who live in France and are enrolled in the French social security system
People who have been diagnosed with multiple sclerosis (based on a standard set of medical guidelines called the McDonald 2017 criteria), whether or not they are currently on treatment for it
People who are already scheduled to have a bladder function test (called a urodynamic assessment) as part of their usual care

Who may not be able to join:

People who are pregnant or breastfeeding
People who are under legal guardianship
People who have a urinary tract infection that has not yet been treated at the time of joining the trial
People who have a known blockage in the urinary tract below the bladder, a known pelvic floor disorder, a type of bladder or urinary tract cancer called urothelial carcinoma, a chronic bladder condition called interstitial cystitis, or who have had a surgical procedure to enlarge the bladder (called augmentation cystoplasty)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 14 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

University Hospital, Toulouse

Registry

ClinicalTrials.gov

Start date

4 December 2023

Est. completion

1 December 2027

Where this trial is recruiting

🇫🇷 France

Primary endpoints

S1P concentration

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov